Table 6.
Comparison of patients with Vancouver type B3 PFF (Means ± SD)
| Group I (TXA) | Group II (No‐TXA) | P‐value | |
|---|---|---|---|
| Cases (n) | 23 | 20 | ‐ |
| Age (years) | 67.6 ± 10.2 | 65.2 ± 12.5 | 0.482* |
| Gender (male/female) | 10/13 | 13/7 | 0.158† |
| BMI (kg/m2) | 23.0 ± 3.8 | 23.3 ± 2.5 | 0.763* |
| Surgical time (min) | 160.7 ± 22.7 | 171.0 ± 28.0 | 0.189* |
| Estimated intraoperative blood loss (mL) | 606.5 ± 319.9 | 990.0 ± 347.8 | 0.001‡ |
| Visible blood loss (mL) | 1014.9 ± 539.6 | 2013.0 ± 713.8 | ˂0.001‡ |
| Hidden blood loss (mL) | 946.2 ± 737.6 | 1945.9 ± 1723.2 | 0.018‡ |
| Allogeneic blood transfusion rate | 60.9% | 95.0% | 0.023† |
| Allogeneic blood transfusion volume (mL) | 563.0 ± 660.1 | 1960.0 ± 1609.9 | <0.001‡ |
| Symptomatic VTE (cases/incidence) | 2 (8.7%) | 1 (5.0%) | 0.900† |
*
Student's t test
†
Pearson's chi‐squared test
‡
Mann–Whitney U test.
BMI, body mass index; PFF, periprosthetic femur fractures; TXA, tranexamic acid; VTE, venous thromboembolism.